An investment company was weighing a major investment in a company with a novel software product for evaluating risk-based monitoring (RBM) in clinical trials. The technology was promising, the category was developing fast, and the regulatory bar was moving with the arrival of the new ICH E6 (R2) guidelines.
To invest with confidence, the client needed more than a financial read. It needed a partner who could go under the hood of clinical trial software, judge it technically and commercially, and map a competitive landscape with little precedent. Bracken was engaged for exactly that depth.
What Made This Difficult
This was an advisory engagement that demanded software fluency, regulatory literacy, and market judgment at once. Four issues defined it.
The RBM software product had to be evaluated technically, not just described commercially.
Market potential had to be assessed against the new ICH E6 (R2) guidelines shaping how monitoring is done.
The competitive landscape was developing and thinly precedented, demanding primary research rather than desk assumptions.
Investor-grade confidence had to be delivered on a compressed, eight-week timeline.
How Bracken Solved It
Bracken combined a technical software evaluation with primary market research and financial modeling, producing a single, decision-ready due-diligence report. The method was rigorous and repeatable.
Technical Software Evaluation
Bracken evaluated the novel RBM SaaS product on its merits and its fit to the ICH E6 (R2) framework, assessing the software itself rather than relying on the vendor's positioning.
Voice of the Customer
The team conducted six customer interviews documenting the product's real advantages and disadvantages in practice.
Market & Competitive Survey
A marketing and competitive survey assessed brand recognition and positioning against the emerging field of alternatives.
Leadership Diligence & SWOT
CEO and key-staff interviews, combined with a structured SWOT analysis, tested the company behind the product.
Financial Modeling & Strategy
Bracken collaborated on Monte Carlo simulations for breakeven and profitability timelines and delivered business-plan and market-penetration recommendations.
Measurable Outcomes
The same rigor that gives an investor confidence tells a software founder what makes a clinical trial product win: technical merit, regulatory fit against standards like ICH E6 (R2), and a defensible position in the market. Bracken understands clinical trial software from the inside, which is why our read is one both investors and builders can trust.
Common Questions
Due diligence on clinical trial software combines a technical evaluation of the product, primary market and customer research, leadership assessment, and financial modeling into a single decision-ready report. In this engagement Bracken delivered all of that in eight weeks, including six customer interviews, a SWOT analysis, and Monte Carlo profitability modeling. The aim is to judge the technology on its merits, not just its pitch.
Evaluating risk-based monitoring software means assessing the product technically, testing it against regulatory expectations such as ICH E6 (R2), and validating its value with real customers and market data. Bracken performed a technical software evaluation alongside six customer interviews and a competitive survey to judge both capability and commercial fit. That combination separates a strong RBM product from a strong sales story.
ICH E6 (R2) is the good clinical practice guideline that formalized risk-based approaches to clinical trial monitoring, making it the benchmark any modern monitoring software must satisfy. Bracken evaluated this product's market potential specifically against ICH E6 (R2), because fit to that framework shapes both adoption and long-term viability. Regulatory alignment is inseparable from commercial potential in this category.
Timelines vary with scope, but a focused, decision-ready due-diligence engagement can be completed in roughly eight weeks, as Bracken did here. That window covered a technical software evaluation, six customer interviews, leadership interviews, a SWOT analysis, and Monte Carlo financial modeling. Speed comes from running technical, market, and financial workstreams in parallel.
